Pertussis (Whooping Cough) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pertussis (Whooping Cough) – Pipeline Review, H2 2016’, provides an overview of the Pertussis (Whooping Cough) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough)

The report reviews pipeline therapeutics for Pertussis (Whooping Cough) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pertussis (Whooping Cough) therapeutics and enlists all their major and minor projects

The report assesses Pertussis (Whooping Cough) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pertussis (Whooping Cough)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Beijing Tiantan Biological Products Co Ltd

Bharat Biotech International Ltd

Biken Inc

Biological E Ltd

Boryung Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

DBV Technologies SA

GlaxoSmithKline Plc

Green Cross Corp

ILiAD Biotechnologies LLC

Indian Immunologicals Ltd

Kaketsuken KK

LG Life Science LTD

NanoBio Corp

Panacea Biotec Ltd

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Ltd

Synthetic Biologics Inc

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pertussis (Whooping Cough) Overview 8

Therapeutics Development 9

Pipeline Products for Pertussis (Whooping Cough) - Overview 9

Pipeline Products for Pertussis (Whooping Cough) - Comparative Analysis 10

Pertussis (Whooping Cough) - Therapeutics under Development by Companies 11

Pertussis (Whooping Cough) - Therapeutics under Investigation by Universities/Institutes 13

Pertussis (Whooping Cough) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Pertussis (Whooping Cough) - Products under Development by Companies 17

Pertussis (Whooping Cough) - Products under Investigation by Universities/Institutes 19

Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development 20

Beijing Minhai Biotechnology Co Ltd 20

Beijing Tiantan Biological Products Co Ltd 21

Bharat Biotech International Ltd 22

Biken Inc 23

Biological E Ltd 24

Boryung Pharmaceutical Co Ltd 25

Daiichi Sankyo Company Ltd 26

DBV Technologies SA 27

GlaxoSmithKline Plc 28

Green Cross Corp 29

ILiAD Biotechnologies LLC 30

Indian Immunologicals Ltd 31

Kaketsuken KK 32

LG Life Science LTD 33

NanoBio Corp 34

Panacea Biotec Ltd 35

Sanofi Pasteur SA 36

Serum Institute of India Ltd 37

Shantha Biotechnics Ltd 38

Synthetic Biologics Inc 39

Zydus Cadila Healthcare Ltd 40

Pertussis (Whooping Cough) - Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 49

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 50

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 51

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 52

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 53

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 54

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 55

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 56

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 57

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 58

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 59

(diphtheria + haemophilus influenzae [serotype B] + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile 60

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 61

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 62

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 63

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 64

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 65

(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile 66

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile 67

(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 68

(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 69

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 70

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 72

(hepatitis B + pertussis) vaccine - Drug Profile 73

bladder cancer + pertussis + tuberculosis vaccine - Drug Profile 74

BVN-002 - Drug Profile 75

Eupenta - Drug Profile 76

GC-3111A - Drug Profile 77

KD-370 - Drug Profile 78

LBVD - Drug Profile 79

pertussis (acellular) vaccine - Drug Profile 80

pertussis (acellular) vaccine - Drug Profile 81

pertussis (whole cell) vaccine - Drug Profile 82

pertussis [strain BPZE1] vaccine - Drug Profile 83

pertussis vaccine - Drug Profile 85

pertussis vaccine - Drug Profile 86

pertussis vaccine - Drug Profile 87

SYN-005 - Drug Profile 89

VN-0103 - Drug Profile 91

VN-0105 - Drug Profile 92

Pertussis (Whooping Cough) - Dormant Projects 93

Pertussis (Whooping Cough) - Discontinued Products 95

Pertussis (Whooping Cough) - Product Development Milestones 96

Featured News & Press Releases 96

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Tables

List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H2 2016 12

Number of Products under Development for Pertussis (Whooping Cough) – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2016 22

Pertussis (Whooping Cough) – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 23

Pertussis (Whooping Cough) – Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2016 24

Pertussis (Whooping Cough) – Pipeline by Bharat Biotech International Ltd, H2 2016 25

Pertussis (Whooping Cough) – Pipeline by Biken Inc, H2 2016 26

Pertussis (Whooping Cough) – Pipeline by Biological E Ltd, H2 2016 27

Pertussis (Whooping Cough) – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 28

Pertussis (Whooping Cough) – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 29

Pertussis (Whooping Cough) – Pipeline by DBV Technologies SA, H2 2016 30

Pertussis (Whooping Cough) – Pipeline by GlaxoSmithKline Plc, H2 2016 31

Pertussis (Whooping Cough) – Pipeline by Green Cross Corp, H2 2016 32

Pertussis (Whooping Cough) – Pipeline by ILiAD Biotechnologies LLC, H2 2016 33

Pertussis (Whooping Cough) – Pipeline by Indian Immunologicals Ltd, H2 2016 34

Pertussis (Whooping Cough) – Pipeline by Kaketsuken KK, H2 2016 35

Pertussis (Whooping Cough) – Pipeline by LG Life Science LTD, H2 2016 36

Pertussis (Whooping Cough) – Pipeline by NanoBio Corp, H2 2016 37

Pertussis (Whooping Cough) – Pipeline by Panacea Biotec Ltd, H2 2016 38

Pertussis (Whooping Cough) – Pipeline by Sanofi Pasteur SA, H2 2016 39

Pertussis (Whooping Cough) – Pipeline by Serum Institute of India Ltd, H2 2016 40

Pertussis (Whooping Cough) – Pipeline by Shantha Biotechnics Ltd, H2 2016 41

Pertussis (Whooping Cough) – Pipeline by Synthetic Biologics Inc, H2 2016 42

Pertussis (Whooping Cough) – Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 43

Assessment by Monotherapy Products, H2 2016 44

Assessment by Combination Products, H2 2016 45

Number of Products by Stage and Target, H2 2016 47

Number of Products by Stage and Route of Administration, H2 2016 49

Number of Products by Stage and Molecule Type, H2 2016 51

Pertussis (Whooping Cough) – Dormant Projects, H2 2016 96

Pertussis (Whooping Cough) – Dormant Projects (Contd..1), H2 2016 97

Pertussis (Whooping Cough) – Discontinued Products, H2 2016 98

List of Figures

List of Figures

Number of Products under Development for Pertussis (Whooping Cough), H2 2016 12

Number of Products under Development for Pertussis (Whooping Cough) – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 44

Assessment by Combination Products, H2 2016 45

Number of Products by Targets, H2 2016 46

Number of Products by Stage and Targets, H2 2016 46

Number of Products by Routes of Administration, H2 2016 48

Number of Products by Stage and Routes of Administration, H2 2016 48

Number of Products by Molecule Types, H2 2016 50

Number of Products by Stage and Molecule Types, H2 2016 50

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports